Alliance Pharma, a global provider of bioanalytical and CMC testing services in the pharmaceu-tical and biopharmaceutical industry, is opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.

Alliance Pharma Pty, Ltd. will contain a state-of-the-art lab, providing small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will now also be able to transfer methods and maintain continuous project manage-ment across their global bioanalytical sites in the U.S. and Europe. Alliance’s opening of the Australian site closely follows their recent acquisition of U.K.-based Drug Development Solu-tions (DDS) from LGC.

“With the speed to start Phase I studies, quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” said Vito Saccente, chief commercial officer, Alliance. “Alliance will not only be able to provide services critical to this market, but also when these compounds move to Phase II, we are well-positioned to trans-fer methods without losing critical knowledge and can continue to support the progression of clinical development for our clients.”

Alliance Pharma Pty, Ltd. President Hao (Jason) Wang, will be leading an experienced team of scientists to provide a broad range bioanalytical services. This new lab is outfitted with the lat-est LC-MS, ligand binding, flow cytometry, ELISpot and PCR instrumentation to support early and late phase research and will be capable of de novo method development, method trans-fers, method validation and sample analysis for pharmacokinetic (PK), biomarkers and immu-nogenicity.

Founded in 2008, Alliance is a contract research organization (CRO) with bioanalytical and CMC testing labs in Malvern, PA, Brisbane, AU, Cambridge, UK and Sandwich, UK. The labs special-ize in advanced research services for all drug molecules, cell and gene therapies, and drug me-tabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs.